首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >[~(18)F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor
【24h】

[~(18)F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor

机译:[〜(18)F] MK-9470,一种用于大麻素-1受体在体内人类PET脑成像的正电子发射断层扫描(PET)示踪剂

获取原文
获取原文并翻译 | 示例
       

摘要

(~(18)F]MK-9470 is a selective, high-affinity, inverse agonist (human IC_(50), 0.7 nM) for the cannabinoid CB1 receptor (CB1R) that has been developed for use in human brain imaging. Autoradiographic studies in rhesus monkey brain showed that [~(18)F]MK-9470 binding is aligned with the reported distribution of CB1 receptors with high specific binding in the cerebral cortex, cerebellum, caudate/putamen, globus pallidus, substantia nigra, and hippocampus. Positron emission tomography (PET) imaging studies in rhesus monkeys showed high brain uptake and a distribution pattern generally consistent with that seen in the autoradiographic studies. Uptake was blocked by pretreatment with a potent CB1 inverse agonist, MK-0364. The ratio of total to nonspecific binding in putamen was 4-5:1, indicative of a strong specific signal that was confirmed to be reversible via displacement studies with MK-0364. Baseline PET imaging studies in human research subject demonstrated behavior of [~(18)F]MK-9470 very similar to that seen in monkeys, with very good test-retest variability (7%). Proof of concept studies in healthy young male human subjects showed that MK-0364, given orally, produced a dose-related reduction in [~(18)F]MK-9470 binding reflecting CB1R receptor occupancy by the drug. Thus, [~(18)F]MK-9470 has the potential to be a valuable, noninvasive research tool for the in vivo study of CB1R biology and pharmacology in a variety of neuropsychiatric disorders in humans. In addition, it allows demonstration of target engagement and noninvasive dose-occupancy studies to aid in dose selection for clinical trials of CB1R inverse agonists.
机译:(〜(18)F] MK-9470是针对大麻素CB1受体(CB1R)的选择性,高亲和力,反向激动剂(人IC_(50),0.7 nM),已开发用于人脑成像。在恒河猴大脑中的研究表明,[〜(18)F] MK-9470结合与在大脑皮层,小脑,尾状/丘脑,苍白球,黑质,黑质和海马中具有高特异性结合的CB1受体的分布相一致。 。在恒河猴中进行正电子发射断层扫描(PET)成像研究表明,脑部摄取量很高,并且分布规律与放射自显影研究中所观察到的一致,用强效CB1反向激动剂MK-0364预处理可阻止摄取。核糖核酸与核糖核酸非特异性结合的比率为4-5:1,表明有很强的特异性信号,已通过MK-0364置换研究证实是可逆的。在人类研究对象中进行的基线PET成像研究证明了[〜(18)F]的行为MK-9470与猴子非常相似,重测变异性非常好(7%)。在健康的年轻男性受试者中进行的概念验证研究表明,口服MK-0364可使[〜(18)F] MK-9470结合剂量降低,反映出该药物对CB1R受体的占用。因此,[〜(18)F] MK-9470有可能成为有价值的,非侵入性的研究工具,可用于体内各种人类神经精神疾病中CB1R生物学和药理学的体内研究。此外,它还可以演示靶点参与和无创剂量占用研究,以帮助选择CB1R反向激动剂的临床试验剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号